Journal
ACS MEDICINAL CHEMISTRY LETTERS
Volume 8, Issue 10, Pages 1031-1036Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.7b00223
Keywords
HDAC6 inhibitors; nexturastat A; melanoma; inflammatory response; immune response
Categories
Funding
- NIH [NS079183, CA184612]
- NIH (MRF CDA grant award)
- CAS [RVO: 86652036]
- project BIOCEV from the ERDF [CZ.1.05/1.1.00/02.0109]
- CSF [15-19640S]
Ask authors/readers for more resources
Only a handful of therapies offer significant improvement in the overall survival in cases of melanoma, a cancer whose incidence has continued to rise in the past 30 years. In our effort to identify potent and isoform-selective histone deacetylase (HDAC) inhibitors as a therapeutic approach to melanoma, a series of new HDAC6 inhibitors based on the nexturastat A scaffold were prepared. The new analogues 4d, 4e, and 7b bearing added hydrophilic substituents, so as to establish additional hydrogen bonding on the rim of the HDAC6 catalytic pocket, exhibit improved potency against HDAC6 and retain selectivity over HDAC1. Compound 4d exhibits antiproliferative effects on several types of melanoma and lymphoma cells. Further studies indicates that 4d selectively increases acetylated tubulin levels in vitro and elicits an immune response through down-regulating cytokine IL-10. A preliminary in vivo efficacy study indicates that 4d possesses improved capability to inhibit melanoma tumor growth and that this effect is based on the regulation of inflammatory and immune responses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available